



**Fresenius Kabi  
Canada Ltd.**

165 Galaxy Blvd, Suite 100  
Toronto, Ontario  
Canada M9W 0C8  
T: 905.770.3711  
F: 844.513.1522  
W: fresenius-kabi.ca

June 1, 2023

## Products Allocation Notice

Dear Valued Customer,

Fresenius Kabi Canada regrets to advise that our **Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL**, **Cefazolin for Injection, USP 10 g PBP Vial 100 mL**, and **Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL** will be placed on allocation effective **June 1, 2023**. Contract customers will be allocated **100% of historical monthly demand**.

DIN	Fresenius Kabi Product Code	MDP Product Code	McKesson Product Code	Product Description	Allocation Date
02236926	C302510	919937	176826	Acyclovir Sodium Injection 50 mg/mL SD Vial 10 mL	100% Allocation <b>Jun. 1, 2023</b>
02237140	103650	974833	127119	Cefazolin for Injection, USP 10 g PBP Vial 100 mL	100% Allocation <b>Jun. 1, 2023</b>
02244622	C601720	922602	2915	Milrinone Lactate Injection 1 mg/mL SD Vial 20 mL	100% Allocation <b>Jun. 1, 2023</b>

We recognize the difficulties and inconvenience that you may encounter as a result of these allocations, and we thank you for your patience and understanding in this matter.

If you have any questions or concerns, please do not hesitate to contact your sales representative.

Sincerely,

Joseph Le  
Senior Manager, Commercial Operations & Analytics  
[joseph.le@fresenius-kabi.com](mailto:joseph.le@fresenius-kabi.com)